NCT04847752 Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
| NCT ID | NCT04847752 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tongji Hospital |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-03-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2021-03-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center prospective cohort study of predictive factors related to prognosis of ischemic stroke due to large-artery atherosclerosis. From March 1, 2021 to December 31, 2026, 1000 patients with ischemic stroke due to large-artery atherosclerosis who are admitted to the Department of Neurology or Neurosurgery, Tongji Hospital are going to be recruited. Detailed clinical data in emergency room and in-hospital will be obtained from the medical record reviews, and the National Institutes of Health Stroke Scale (NIHSS) and Modified Rankin Scale (mRS) score will be done by certified neurologists to assess the severity of the disease in acute stage and treatment outcome during the follow-up. All cases will undergo routine blood tests, brain magnetic resonance imaging (MRI) and cerebral vascular examination, such as TCD, CTA, HRMR or DSA. The investigators will analyze the in-hospital factors that could predict the outcome to provide more evidence-based suggestions in the treatment and prognosis of atherosclerotic ischemic cerebrovascular disease.
Eligibility Criteria
Inclusion Criteria: * Ischemic stroke due to large-artery atherosclerosis has been proved by clinical symptoms and imaging examinations. * Symptomatic superior arch stenosis \>50% * Asymptomatic superior arch stenosis was \>70% * written informed consent was obtained from patients or their surrogates before enrollment. Exclusion Criteria: * Brain CT or MRI showing cerebral hemorrhage (excluded ischemic stroke with hemorrhage transformation) * With severe systemic disease, are expected to survive \< 3 months * Patients will not able to provide continuous follow-up information
Contact & Investigator
Dai-Shi Tian, Dr.
STUDY CHAIR
Tongji Hospital
Frequently Asked Questions
Who can join the NCT04847752 clinical trial?
This trial is open to participants of all sexes, up to 80 Years, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04847752 currently recruiting?
Yes, NCT04847752 is actively recruiting participants. Contact the research team at tiands@tjh.tjmu.edu.cn for enrollment information.
Where is the NCT04847752 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT04847752 clinical trial?
NCT04847752 is sponsored by Tongji Hospital. The principal investigator is Dai-Shi Tian, Dr. at Tongji Hospital. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.